Recent Updates
Recently added Catalysts
VNRX Neutral Sentiment

Capture-PCR™ Product Brochure

Friday, September 20, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article presents a product brochure for Capture-PCR™, highlighting its relevance in cancer diagnostics. It also references related articles discussing the prognostic value of the Nu.Q® cancer test and research on chromatin accessibility in neutrophils linked to sepsis. The content encourages subscriptions for updates on Volition products.
Price reaction · baseline $12.7 (2024-09-19 close) · hit pre-market · clean, no other VNRX news in the window
day 0 close · peak
+3.9%

Market Sentiment Analysis

Full Press Release Details

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is Capture-PCR™?

Capture-PCR™ is a product related to cancer diagnostics.

What does the brochure highlight?

The brochure highlights the relevance of Capture-PCR™ in cancer diagnostics.

What related articles are mentioned?

The articles discuss the Nu.Q® cancer test and chromatin accessibility in neutrophils.

How can I get updates on Volition products?

You can subscribe for updates on Volition products via the provided link.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare Capture-PCR™ Nu.Q® cancer test sepsis diagnostics
Last updated: Sep 20, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk